3Beasley B N, Unger E F, Temple R. Anticoagulant options-- why the FDA approved a higher but not a lower dose of dabigatran [J]? N Engl J Med, 2011,364(19) : 1788-1790.
4Wienen W, Stassen J M, Priepke H, et al. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate [J]. Thromb Haemost, 2007,98(2) : 155-162.
5Stangier J, Rathgen K, Stahle H, et al. Influence of renal impairment on the pharmacokineties and pharmacodynamics of oral dabigatran etexilate: An open-label, parallel-group, single-centre study [J]. Clin Pharmacokinet, 2010, 49 (4) : 259-268.
6Ezekowitz M D, Reilly P A, Nehmiz G, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (petro study) [J]. Am J Cardiol, 2007,100(9) : 1419-1426.
7Connolly S J, Ezekowitz M D, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation [J]. N Engl J Med, 2009,361(12) : 1139-1151.
8Flaker G, Ezekowitz M, Yusuf S, et al. Efficacy and safety of dabigatran compared to warfarin in patients with paroxysmal, persistent, and permanent atrial fibrillation: Results from the RE-LY (randomized evaluation of long-term anticoagulation therapy) study [J]. J Am Coil Cardiol, 2012,59(9):854-855.
9Diener H C, Connolly S J, Ezekowitz M D, et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: A subgroup analysis of the REe-LY trial [J]. Lancet Neurol, 2010,9(12): 1157-1163.
10Nagarakanti R, Ezekowitz M D, Oldgren J, et al. Dabigatran versus warfarin in patients with atrial fibrillation: An analysis of patients undergoing cardioversion [J]. Circulation, 2011, 123(2) : 131-136.
